AbCellera Biologics Inc.
ABCL$671M
Small CapNASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaVANCOUVER596 employees
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Feb 15, 2027
48wMarket Overview
Stock performance and key metrics
ABCL News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ABCL635 | Phase 2 | Vasomotor Symptoms Associated With Menopause | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply